The European Union's drug regulator has been reviewing wider use of the highly popular weight-loss drug Wegovy to include reducing the risk of strokes and heart attacks, adding to its approved use to tackle obesity. While U.S. regulatory approval to reduce heart risk was granted earlier in March, Novo has said it expects Chinese and European Union regulators to decide on an expanded heart risk label during the second half of the year. The EU's review is based on a trial known as Select, which showed that the drug can reduce the risk of heart attacks, strokes or death from heart disease by 20% in certain overweight people who have already had serious cardiovascular problems. The favourable guidance by G-BA is likely to have repercussions beyond the use of Wegovy because Novo's rival Eli Lilly has also been running trials to show additional health benefits of its weight-loss drug Mounjaro, also known as tirzepatide.